ICON to Acquire Clinical Research Management, Inc.
2016年6月30日 - 9:00PM
ビジネスワイヤ(英語)
Acquisition extends ICON’s presence in the
market for government sponsored research and enhances capabilities
in Vaccines and Infectious Disease
ICON plc, (NASDAQ:ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it has agreed, subject to certain customary closing conditions
(including applicable regulatory approvals), to acquire Clinical
Research Management, Inc. (ClinicalRM). The acquisition will
enhance ICON’s ability to access the market for government
sponsored research and further enhances ICON’s capabilities in the
areas of Vaccines and Infectious Disease.
ClinicalRM provide full service and functional research
solutions to a broad range of US government agencies. Their
extensive expertise extends across basic and applied research,
infectious diseases, vaccines development and testing and the
response to bio-threats. They have worked in collaboration with
government and commercial customers to respond to the threat of
global viral epidemics.
Commenting on the acquisition, ICON’s Chief Executive Officer,
Ciaran Murray said: “The market for government sponsored research
is significant with over fifteen hundred active clinical studies
being funded by the National Institutes of Health or other federal
agencies. ClinicalRM has strong relationships and a deep
understanding of what is required to partner successfully with
government sponsors. They will provide ICON a platform to further
penetrate this market segment as part of our strategy to grow and
diversify our customer base. ClinicalRM’s experience in responding
to the challenges of global viruses will further enhance ICON’s
capabilities in the areas of Vaccines and Infectious disease,
benefiting our customers and patients globally.”
Victoria Tifft, Chief Executive Officer of ClinicalRM added, “We
are delighted to be joining ICON. By combining ClinicalRM’s
expertise in government sponsored research with ICON’s breadth of
services and global footprint we will be able to bring additional
services and thought leadership to our customers. We are also
excited about the potential the combination has to further innovate
drug development in the area of Vaccines and Infectious diseases,
important areas of focus for both government and commercial
customers.”
About ClinicalRM
ClinicalRM is a full-service Contract Research Organization
specializing in preclinical through Phase IV support of clinical
research and clinical trial services for biologics, drugs and
devices. The organization helps customers get their products to
market faster with a wide array of research, regulatory and sponsor
services within the U.S. and around the globe. From international
partnerships and affiliations to government relations and local
alliances, ClinicalRM delivers a synergy in the global market with
projects spanning the government, academic and commercial
marketplaces. The company has a distinct ability to provide
boots-on-the-ground and rapid response efforts to global health
crises. More information is at http://www.clinicalrm.com/.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 89 locations in 37 countries and has approximately
12,200 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160630005430/en/
ICON plcNiamh Murphy, +35312912180niamh.murphy@iconplc.com
ICON (NASDAQ:ICLR)
過去 株価チャート
から 9 2024 まで 10 2024
ICON (NASDAQ:ICLR)
過去 株価チャート
から 10 2023 まで 10 2024